Oculis Holding AG (OCS) Retained Earnings (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Retained Earnings came in at -$527.9 million in Q1 2026, down 48.88% year-on-year from -$1.0 billion in Q1 2025, and down 9.72% quarter-over-quarter from -$481.1 million in Q4 2025.
Oculis Holding AG (OCS) Retained Earnings (2021 - 2026) Analysis & Trends
Oculis Holding AG's Retained Earnings history runs 6 years deep, the most recent figure standing at -$527.9 million for Q1 2026.
- On a quarterly basis, Retained Earnings fell 48.88% year-over-year to -$527.9 million in Q1 2026; TTM through Mar 2026 was -$527.9 million, a 48.88% decrease from a year earlier, with the FY2025 full-year figure at -$463.8 million, down 42.88% from the prior year.
- Retained Earnings declined to -$527.9 million in Q1 2026 per OCS's latest filing, from -$481.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$115.2 million in Q4 2022 and bottomed at -$527.9 million in Q1 2026.
- The 5-year median for Retained Earnings is -$296.5 million (2024), against an average of -$315.6 million.
- Across the five-year window, Retained Earnings slumped 95.51% in 2023 and slumped 38.55% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$115.2 million in 2022, then sank by 95.51% to -$225.2 million in 2023, then tumbled by 44.73% to -$326.0 million in 2024, then tumbled by 47.59% to -$481.1 million in 2025, then fell by 9.72% to -$527.9 million in 2026.
- Per Business Quant, the three latest OCS Retained Earnings figures stand at -$527.9 million (Q1 2026), -$481.1 million (Q4 2025), and -$451.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -527.87 Mn |
| Dec 31, 2025 | -481.09 Mn |
| Sep 30, 2025 | -451.29 Mn |
| Jun 30, 2025 | -415.69 Mn |
| Mar 31, 2025 | -354.55 Mn |
| Dec 31, 2024 | -325.97 Mn |
| Sep 30, 2024 | -296.52 Mn |
| Jun 30, 2024 | -261.75 Mn |
| Mar 31, 2024 | -247.32 Mn |
| Dec 31, 2023 | -225.22 Mn |
| Sep 30, 2023 | -212.03 Mn |
| Jun 30, 2023 | -188.93 Mn |
| Dec 31, 2022 | -115.20 Mn |
| Dec 31, 2021 | -78.39 Mn |